Abstract: Systems, computer program products, and methods are described herein for source independent but source value dependent transfer monitoring.

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to systems and methods for automatically shutting off fluid flow through a fluid inlet line of a water heater upon detection of a leak of the water heater. The system may include an electrically powered shutoff assembly operatively coupled to the fluid inlet line, and a capacitor operatively coupled to the electrically powered shutoff assembly. The electrically powered shutoff assembly may be configured to shut off fluid flow through the fluid inlet line upon detection of a leak of the water heater, and the capacitor may be configured to store power received from an external power source. Accordingly, when the electrically powered shutoff assembly does not have access to electric power, the capacitor may power the electrically powered shutoff assembly to shut off fluid flow through the fluid inlet line.

Abstract: The invention provides a method of selecting a polyether polysiloxane surfactant to optimise an alcohol and water containing foaming cleansing composition selecting an amount of alcohol to be used in the final composition; and selecting the degree of polymerisation of the backbone of the siloxane (PDMS) of the polyether polysiloxane surfactant and the degree of polymerisation of polyether side groups of the polyether polysiloxane surfactant for that amount of alcohol from a predetermined optimisation calibration, where the alcohol is a C1 to C4 straight or branched chain alcohol, the polysiloxane backbone is polydimethylsiloxane (PDMS) and the polyether is selected from a polyethylene oxide (PEO), polypropylene oxide (PPO) or a mixed PEO/PPO polyether.

Abstract: A modular platform system includes a base module and at least one extension module. One side of the base module has a recess for receiving a connector on one side of the extension module to connect the extension module to the base module. The extension module may include a recess for receiving a connecting member on a second extension module to connect the second extension module to the extension module.

Abstract: A composition comprises a cohort of at least five isolated unique strains of a single species of bacteria, wherein the species of bacteria is represented in the mammalian microbiome, and wherein the cohort of isolated strains exhibit different and diverse catabolic capability thereby increasing the chances that one or more of the strains in the composition will find a nutritional niche in the infant GI tract.

Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.

Abstract: A system and a method for updating hierarchical family trees of organizations having related corporate members. The system includes a data processor; a memory for storing instructions for operation of the data processor, the instructions causing the processor to perform steps of accessing a comprehensive linkage repository having corporate linkage data stored therein; determining changes in the corporate linkage data; generating a change file representative of the changes in the corporate linkage data; using the change file to generate exceptions to the corporate linkage data stored in the repository; generating an updated hierarchical family tree in accordance with the exceptions; and storing the updated hierarchical family tree.

Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.

Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.

Abstract: An integral ankle support for a shoe has a support element and a cushioning element. The support element has horizontally elongated, generally parallel, and panel-like edge upstanding wings having corresponding front and rear ends joined at their rear ends by an integral, curved, and edge upstanding bight panel portion. The support element is constructed of semi-rigid, but partially flexible, material that is lightweight and moldable. The support element has a bottom tab that is oriented substantially perpendicular to the wings and that extends inwardly under the insole of the shoe. The ankle cushioning element is located on the inner surfaces of the rear ends of the wings and the central portion of the lower margin of the bight panel portion. The ankle support is incorporated as part of the internal structure of the shoe so as to remain fixed in place and provide enhanced support to the wearer's foot.

Abstract: An integral ankle support for a shoe has a support element and a cushioning element. The support element has horizontally elongated, generally parallel, and panel-like edge upstanding wings having corresponding front and rear ends joined at their rear ends by an integral, curved, and edge upstanding bight panel portion. The support element is constructed of semi-rigid, but partially flexible, material that is lightweight and moldable. The support element has a bottom tab that is oriented substantially perpendicular to the wings and that extends inwardly under the insole of the shoe. The ankle cushioning element is located on the inner surfaces of the rear ends of the wings and the central portion of the lower margin of the bight panel portion. The ankle support is incorporated as part of the internal structure of the shoe so as to remain fixed in place and provide enhanced support to the wearer's foot.

Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.

Abstract: A method of electronically producing lesson plans and/or teaching units and the like using a three-dimensional structure comprising different educational frameworks and strategies. A master matrix is employed, the development pages (4) of which represent a multiple learning intelligence and a cognitive learning level. Each development page comprises prompts for generating questions and/or activities, the final lesson plan being produced from selected questions and/or activities.

Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.